Human safety of free Hydroquinone derived from herbal medicinal p | 16561
Journal of Drug Metabolism & Toxicology

Journal of Drug Metabolism & Toxicology
Open Access

ISSN: 2157-7609

Human safety of free Hydroquinone derived from herbal medicinal products containing Uvae ursi folium

International Conference on Toxicogenomics and Drug Monitoring

August 25-27, 2015 Valencia, Spain

Susana Garcia de Arriba

Schaper & Br�?¼mmer GmbH & Co. KG, Germany

Scientific Tracks Abstracts: J Drug Metab Toxicol

Abstract :

Uvae ursi folium (bearberry leaf) has been traditionally used to treat symptoms of lower urinary tract infections. Arbutin, the major active constituent, is rapidly absorbed in the small intestine and undergoes hepatic conjugation to form hydroquinone (HQ) conjugates. Because arbutin is broken down to yield free HQ, concerns regarding the safety of free HQ have raised serious questions about the safety of herbal preparations containing extracts of Uvae ursifolium. Data on pharmacokinetics in humans helped to estimate human exposure to free HQ: 11 �?¼g/kg body weight /day in urine after the therapeutic daily dose of 420 mg arbutin. The permitted daily exposure of free HQ in humans was estimated at 100 �?¼g/kg body weight/day. Dietary sources of arbutin/HQ generate comparable free HQ exposure levels as therapeutic doses of Uvae ursifolium. No direct evidence has been found supporting the toxicity of free HQ derived from herbal medicinal products. On the other hand, the mutagenic potential of free HQ derived from a therapeutic dose of Uvae ursifolium extract (1,6 g Uvae ursifolium extract corresponding to 420 mg arbutin) was investigated in urine samples of healthy volunteers (n=12). Free and total HQ were firstly estimated in single urine samples. Both, the in vitro AMES assay and the in vivo micronucleus assay were negative for mutagenicity activity. Therefore, urine samples obtained from healthy volunteers receiving an Uvaursi folium extract at the same dose as proposed for therapeutic use bears no mutagenic risk.

Biography :

Susana Garcia de Arriba studied Pharmacy at the University of Valencia, Spanien. Her M.Sc. in Pharmaceutical Science completed at the Faculty of Pharmacy, University of Gent, Belgium. She completed her PhD in Pharmacology at the University of Leipzig (Germany). She worked as postdoctoral fellow at the Rudolf- Boehm Institute of Pharmacology and Toxicology as well as at the Interdisciplinary Center for Clinical Research (IZKF), Neuro-immunological Cell Biology Unit, University of Leipzig. Since July 2008 works for the company Schaper & Brümmer as Scientific & Medical Expert inside of the department of Regulatory Affairs in Salzgitter Ringelheim, Germany. Her areas of expertise are Herbal Medicinal Products, Phytotherapy, processes of Aging, Neurodegeneration, mechanism of drug action and mechanism of drug toxicity.